Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Health's Q3 Revenues Rise 77 Percent on Oncotype DX Sales

NEW YORK (GenomeWeb News) – Genomic Health reported after the close of the market on Wednesday that its third-quarter revenues rose 77 percent due to increased sales of its Oncotype DX breast cancer assay.
The Redwood City, Calif.-based firm brought in revenues of $28.1 million for the three-month period ended Sept. 30, compared to revenues of $15.9 million for the third quarter of 2007. Nearly all of the revenues for the most recent quarter came from Oncotype DX sales, as contract revenues represented only $51,000 of the total compared with contract revenues of $120,000 in the comparable period a year ago.
Genomic Health cut its year-over-year net loss by more than half. For the quarter, it's loss was $3 million, or $.11 per share, compared to a loss of $7.3 million, or $.26 per share, for the comparable quarter of 2007.
Its R&D spending increased 23 percent to $6.9 million from $5.6 million, and its SG&A spending rose 24 percent to $17.3 million from $14 million.
“This quarter, we again increased the value of Oncotype DX by the inclusion of quantitative HER2 scores, while continuing to invest in our commercial organization here and abroad,” Genomic Health Chairman and CEO Randy Scott said in a statement.
The firm also noted that during the quarter it delivered more than 10,220 test results to customers, an increase of 72 percent year over year. It also gained Oncotype DX reimbursement coverage for 7.9 million lives and now has coverage for around 89 percent of insured lives, the firm said.
Genomic Health finished the quarter with $9.5 million in cash and cash equivalents.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.